Cargando…
P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621487/ http://dx.doi.org/10.1097/01.HS9.0000890816.89900.95 |
| _version_ | 1784821566936186880 |
|---|---|
| author | Fedorova, Liudmila Lepik, Kirill Mikhailova, Natalia Kondakova, Elena Komarova, Yaroslava Kotselyabina, Polina Borzenkova, Evgenia Baykov, Vadim Moiseev, Ivan Kulagin, Alexander |
| author_facet | Fedorova, Liudmila Lepik, Kirill Mikhailova, Natalia Kondakova, Elena Komarova, Yaroslava Kotselyabina, Polina Borzenkova, Evgenia Baykov, Vadim Moiseev, Ivan Kulagin, Alexander |
| author_sort | Fedorova, Liudmila |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621487 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96214872022-11-01 P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma Fedorova, Liudmila Lepik, Kirill Mikhailova, Natalia Kondakova, Elena Komarova, Yaroslava Kotselyabina, Polina Borzenkova, Evgenia Baykov, Vadim Moiseev, Ivan Kulagin, Alexander Hemasphere Immunotherapy Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621487/ http://dx.doi.org/10.1097/01.HS9.0000890816.89900.95 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Immunotherapy Fedorova, Liudmila Lepik, Kirill Mikhailova, Natalia Kondakova, Elena Komarova, Yaroslava Kotselyabina, Polina Borzenkova, Evgenia Baykov, Vadim Moiseev, Ivan Kulagin, Alexander P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma |
| title | P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma |
| title_full | P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma |
| title_fullStr | P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma |
| title_full_unstemmed | P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma |
| title_short | P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma |
| title_sort | p062: the efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic hodgkin lymphoma |
| topic | Immunotherapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621487/ http://dx.doi.org/10.1097/01.HS9.0000890816.89900.95 |
| work_keys_str_mv | AT fedorovaliudmila p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT lepikkirill p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT mikhailovanatalia p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT kondakovaelena p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT komarovayaroslava p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT kotselyabinapolina p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT borzenkovaevgenia p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT baykovvadim p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT moiseevivan p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT kulaginalexander p062theefficacyandsafetyofnivolumab40mgtherapyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma |